Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
BioNTech Is More Than a Covid-19 Stock. It’s Having a Great September.
BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...
BioNTech raised to buy at Jefferies on new cancer drug
BioNTech (BNTX) stock traded higher on Tuesday after Jefferies upgraded the COVID-19 vaccine maker to Buy, citing the ...
BioNTech SE: A Strong Buy on BNT327’s Promising Cancer Treatment Prospects and Financial Fortitude
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...
The Pharma Letter2d
ESMO 2024: Encouraging mid-stage results on BioNTech asset
PM8002/BNT327 is a bispecific antibody targeting PD-L1 and VEGF-A. BioNTech agreed to pay up to $1 billion to develop the drug in an agreement with Biotheus signed in November last year. Results have ...
Buy Rating Reiterated for BioNTech SE on Promising Oncology Pipeline and BNT327’s Potential
In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on BioNTech SE (BNTX – Research Report), ...
businessupturn14d
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “At this year’s ESMO, we will present data from three clinical trials with BNT327/PM8002, one of the key backbones for our ...
The Bakersfield Californian14d
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio ...
(Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European ...